期刊文献+

骨原发尤文肉瘤预后相关因素的分析 被引量:3

Ewing's sarcoma of bone: treatment results and prognostic factors
原文传递
导出
摘要 目的 明确骨原发尤文肉瘤患者的治疗结果,分析影响预后相关因素.方法 回顾性分析1998年7月至2007年7月就诊的78例骨原发尤文肉瘤患者的临床资料.通过随访了解肿瘤学预后,明确5年总体生存率及局部复发率.通过回顾病例,分析年龄、性别、肿瘤部位、肿瘤大小、初次诊断时有无转移、乳酸脱氢酶、碱性磷酸酶水平、治疗方式、外科边界等因素对总体生存率的影响.利用Kaplan-Meier生存分析确定对生存有影响的单个因素,并通过Cox回归分析明确影响预后的独立危险因素.结果 53例患者获得随访,中位随访时间37.6个月(8.0~101.0个月).患者5年总体生存率为33.7%,局部复发率20.8%,中位复发时间20个月.单因素分析结果显示:年龄<20岁、初诊时元转移、病变位于四肢、肿瘤直径<10 cm、取得广泛外科边界的患者预后较好(P<0.05);多因素分析显示初诊时转移情况、肿瘤部位、肿瘤直径是影响预后的独立危险因素.结论 初诊时有无转移、肿瘤的部位和大小是影响骨尤文肉瘤预后的独立危险因素. Objective To determine the prognostic factors from the view of clinic and pathology.Methods A retrospective analysis was performed on a data set of 78 patients with Ewing's sarcoma treated at Peking University People's Hospital Musculoskeletal tumor center between July 1998 and July 2007. Fiveyear overall survival(OS), reccurence rate and prognostic factors were analyzed in this study. Univariate and multivariate analysis were performed to determine the prognostic factors for OS. Results Fifty-three cases were followed up, follow-up time ranged from 8.0 to 101.0 months (median 37.6 months). The 5-year overall survival rate and local reccurence rate were 33.7% and 20.8% respectively. Univariate showed age 〈20 years, metastases free at diagnosis, tumor located at extremities, tumor size 〈10 cmm, adequate surgical margin had better survival rate( all P 〈0.05). Multivariate analysis demonstrated that metastases at diagnosis, primary site and tumor size were independent prognostic factors for OS. Conclusion The independent prognostic factors Ewing's sarcoma are metastases at diagnosis, primary site,tumor size.
出处 《中华外科杂志》 CAS CSCD 北大核心 2010年第12期896-899,共4页 Chinese Journal of Surgery
关键词 肉瘤 Ewing’s 预后 存活率 Sarcoma,Ewing's Prognosis Survival rate
  • 相关文献

参考文献14

  • 1Meyer WH,Kun L,Marina N,et al.Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.J Clin Oncol JT,1992,10:1737-1742.
  • 2Bacci G,Forni C,Longhi A,et al.Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies.402 patients treated at Rizzoli between 1972 and 1992.Eur J Cancer,2004,40:73-83.
  • 3Paulussen M,Ahrens S,Burdach S,et al.Primary metastatic (stage Ⅳ) Ewing tumor:survival analysis of 171 patients from the EICESS studies.European Intergroup Cooperative Ewing Sarcoma Studies.Ann Oncol,1998,9:275-281.
  • 4Grier HE,Krailo MD,Tarbell NJ,et al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.N Engl J Med,2003,348:694-701.
  • 5Cangir A,Vietti TJ,Gehan EA,et al.Ewing's sarcoma metastatic at diagnosis.Results and comparisons of two intergroup Ewing's sarcoma studies.Cancer,1990,66:887-893.
  • 6Cotterill SJ,Ahrens S,Paulussen M,et al.Prognostic factors in Ewing's tumor of bone:analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group.J Clin Oncol,2000,18:3108-3114.
  • 7Hayes FA,Thompson El,Meyer WH,et al.Therapy for localized Ewing's sarcoma of bone.J Clin Oncol JT,1989,7:208-213.
  • 8Jurgens H,Exner U,Gadner H,et al.Multidisciplinary treatment of primary Ewing's sarcoma of bone.A 6-year experience of a European Cooperative Trial Cancer,1988,61:23-32.
  • 9Craft AW,Cotterill SJ,Bullimore JA,et al.Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1).United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party.Eur J Cancer,1997,33:1061-1069.
  • 10Bacci G,Forni C,Longhi A,et al.Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies 402 patients treated at Rizzoli between 1972 and 1992.Eur J Cancer JT,2004,40:73-83.

同被引文献49

  • 1张光明,徐中和,王建炜.旋转成形术对骨肿瘤保肢的临床应用[J].中国临床解剖学杂志,2004,22(4):439-440. 被引量:2
  • 2Huang M, Lucas K. Current therapeutic approaches in meta- static and recurrent Ewing sarcoma[J]. Sarcoma, 2011,9 (3) .- 275-281.
  • 3Bacci G,Forni C, Longhi A, et al. Long-term outcome for pa tients with non metastatic Ewing's sarcoma treated with adju- vant and neoadjuvant cbemotherapies. 402 ptltients treated at Rizzoli between 1972 and 1992[J]. EurJ Cancer,200,1,40(1): 73-83.
  • 4魏敏.于雁.肺癌脑转移的化疗研究进展[J].肿瘸研究与临床.2012.24(1):67-69.
  • 5Esiashvili N, Goodman M, Marcus RB, et al. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades : sur- veillance, epidemiology, and end results data [J].J Pediatr Hematol Oncol, 2008, 30 (6) : 425 - 430.
  • 6Worch J, Matthay KK, Neuhaus J, et al.Ethnic and racial differences in patients with Ewing sarcoma [ J ]. Cancer, 2010, 116 (4) : 983 -988.
  • 7Potratz J, Dirksen U, Jurgens H, et al. E- wing sarcoma: clinical state - of - the - art [ J ]. Pediatr Hematol Oncol, 2012, 29 (1): 1-11.
  • 8Amdt CA, Rose PS, Folpe AL, et al. Com- mon musculoskeletal tumors of childhood and adolescence [J]. Mayo Clin Proc, 2012, 87 (5) : 475 - 487.
  • 9Abed YY, Beltrami G, Campanacci DA, et al. Biological reconstruction after resection of bone tumours around the knee : long - term follow - up [J]. J Bone Joint Surg Br, 2009, 91 (10): 1366 -1372.
  • 10Highsmith MJ, Kahle JT, Bongiomi DR, et al. Safety, energy efficiency, and cost efficacy of the C - Leg for transfemoral amputees: a review of the literature [ J ]. Prosthet Orthot Int, 2010, 34 (4): 362-377.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部